Project Grant R01CA288731
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$440K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports fundamental research aimed at understanding the biological mechanisms underlying acute myeloid leukemia (AML) development and progression. The $487,973 award to The Leland Stanford Junior University will fund a 5-year project investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in AML pathogenesis. The research will explore the clonal evolution, kinetics, and cell...
This $135,594 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award aims to develop novel pharmacological approaches to rewire oncogenic gene expression and induce apoptosis in cancer cells, with a focus on aggressive leukemias driven by mixed-lineage leukemia (MLL) gene translocations. The research will involve organic synthesis, pharmacological assays, chromatin mechanism studies, cellular model...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $458,698 to the Regents of the University of Michigan to conduct research aimed at understanding the fundamental biological mechanisms underlying acute myeloid leukemia (AML) relapse. The research will focus on identifying novel gene drivers that confer therapy resistance and contribute to the competitive regrowth of leukemic cells after initial treatment, which is a major barrier...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $768,437.00 to the Sanford Burnham Prebys Medical Discovery Institute (SBP) to conduct research aimed at identifying chemical compounds that inhibit the chromatin reader SGF29, which has been identified as a regulator of oncogene transcription in acute myeloid leukemia (AML). The goal of the project is to implement high-throughput screening assays developed by SBP to discover...
This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to investigate the impacts of newly developed small molecule degraders that target the heat shock transcription factor 1 (HSF1) on acute myeloid leukemia (AML) stem cells. The $502,516 award to Case Western Reserve University, effective April 1, 2025 through March 31, 2030, will support research to determine the cellular effects of these HSF1 degraders on AML stem cell self-renewal, elucidate...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand the fundamental biological mechanisms underlying acute myeloid leukemia (AML). The $483,760 award, effective April 1, 2025 through March 31, 2030, will enable The Trustees of the University of Pennsylvania to investigate the role of the DCAF15 E3 ligase in regulating the cohesin complex and genome architecture in AML. Key objectives include deciphering the...
This Project Grant award, valued at $678,101, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF). The funding supports a 5-year research project to develop a novel radioimmunotherapy targeting the active conformation of integrin beta-2 as a potential best-in-class treatment for acute myeloid leukemia (AML). The key objectives are to: 1) evaluate the preclinical efficacy...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Case Western Reserve University to investigate a novel combination therapy approach for acute myeloid leukemia (AML). The $491,357 award, granted on March 15, 2025, aims to establish the mechanistic role of mTOR hyperactivation as a chemosensitizer for AML. Key objectives include mapping mitochondrial respiratory defects, identifying AML cell susceptibility to metabolic...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program 93.395 Cancer Treatment Research (CFDA 93.395), is funding the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The $402,600 award, granted on Apr 3, 2025, supports research by the Sloan-Kettering Institute for Cancer Research to: (1) test the efficacy and...